Iscar for Second Line Treatment of Advanced Non-Small Cell Lung Cancer
Not Applicable
Completed
- Conditions
- Non-Small Cell Lung Cancer
- Registration Number
- NCT00283478
- Lead Sponsor
- Kentuckiana Cancer Institute
- Brief Summary
To determine if Iscar Quercus improves immune function and quality of life among patients with stage IV non-small cell lung cancer.
- Detailed Description
RAndomized pilot study of supplemental Iscar in combination with Gemcitabine vs. Gemcitabine alone as second line treatment for advanced non-small cell lung cancer.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 20
Inclusion Criteria
- newly diagnosed IIIB and IV NSCLC who have failed one prior line of chemo
- Karnofsky score 60% or greater
- patients who will be treated with Gemcitabine
Exclusion Criteria
Not provided
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Primary Outcome Measures
Name Time Method To determine if Iscar improves immune function and quality of life.
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms does Iscar Quercus use to enhance immune function in stage IV NSCLC patients?
How does Iscar supplementation compare to other immune-boosting agents in second-line NSCLC therapy?
Are there specific biomarkers that correlate with improved quality of life in NSCLC patients using Iscar?
What are the potential adverse events associated with Iscar and gemcitabine combination therapy in NSCLC?
What other natural compounds show promise in combination with gemcitabine for advanced NSCLC treatment?
Trial Locations
- Locations (1)
Kentuckiana Cancer Institute
🇺🇸Louisville, Kentucky, United States
Kentuckiana Cancer Institute🇺🇸Louisville, Kentucky, United States